
HCA Healthcare (HCA) Stock Forecast & Price Target
HCA Healthcare (HCA) Analyst Ratings
Bulls say
HCA Healthcare reported impressive financial metrics in its 3Q25 results, including a same-facility revenue increase of 9.2% and a year-over-year increase of 7.1% in inpatient revenue per admission, indicating strong demand for its services. The company's management raised its 2025 adjusted EBITDA guidance to a range of $15.25 billion to $15.65 billion, driven significantly by core operational outperformance. The growth in Medicare Advantage volumes by 4.8% year-over-year, alongside a favorable payer mix contributing to higher admission pricing, further highlights HCA's operational strength and resilience in a competitive market.
Bears say
HCA Healthcare's total debt to last twelve months (LTM) EBITDA ratio decreased to 2.9x in the third quarter of 2025, indicating a potential easing of its leverage concerns; however, prolonged pressure on earnings growth and valuation remains evident. The company's anticipated 5% headwind to earnings estimates and subsequent multiple contraction to an 8.75x valuation underline a cautious outlook for future profitability. Additionally, despite slight improvements in supply expenses, the growth estimate for 2026 at $16.052 billion reflects a suboptimal trajectory, positioning it below the company's long-term growth expectations amidst broader economic uncertainties.
This aggregate rating is based on analysts' research of HCA Healthcare and is not a guaranteed prediction by Public.com or investment advice.
HCA Healthcare (HCA) Analyst Forecast & Price Prediction
Start investing in HCA Healthcare (HCA)
Order type
Buy in
Order amount
Est. shares
0 shares